MK-677

MK-677, known as Ibutamoren, is not a SARM. It is an orally active, non-peptidic growth hormone secretagogue that mimics the action of ghrelin at the growth hormone secretagogue receptor (GHS-R1a). Developed by Merck, MK-677 stimulates the anterior pituitary to release endogenous growth hormone in a pulsatile, physiological pattern — distinguishing it from exogenous GH administration, which delivers a single supraphysiological bolus. It is commonly categorized alongside SARMs due to its complementary application in performance and recovery research.

MK-677 binds to the GHS-R1a receptor in the hypothalamus and pituitary, triggering a signaling cascade that increases circulating growth hormone (GH) and, consequently, insulin-like growth factor 1 (IGF-1). Clinical trials have demonstrated sustained GH and IGF-1 elevation of 40–60% above baseline with chronic administration, without desensitization of the GH axis over periods up to 24 months. Importantly, MK-677 does not suppress endogenous GH production — it amplifies the body's own secretory pulses, preserving the natural circadian rhythm of GH release.

Research consistently highlights MK-677's benefits for recovery optimization, sleep architecture improvement, muscle preservation during caloric deficit, and connective tissue repair. Published human studies demonstrate increased lean body mass, improved nitrogen balance, enhanced REM sleep duration and quality, increased bone mineral density, and accelerated wound healing. Its capacity to elevate IGF-1 makes it particularly valuable in protocols targeting tissue repair and anti-aging.

MK-677 is suited for researchers at any experience level, as it does not interact with the androgen receptor and produces no hormonal suppression. It is an ideal foundational compound for recovery-focused protocols, GH optimization without injectable peptides, and as an adjunct to SARM or anabolic cycles for enhanced recovery and sleep quality. Researchers focused on body recomposition frequently pair MK-677 with RAD-140 or LGD-4033.

MK-677 has an elimination half-life of approximately 24 hours, permitting once-daily dosing. Oral bioavailability is excellent. Because it does not engage the androgen receptor, there is zero testosterone suppression and no PCT requirement. Notable considerations include transient appetite increase (via ghrelin mimicry, typically subsiding within 2–3 weeks), mild water retention, and potential elevation of fasting blood glucose and insulin resistance with prolonged use. Researchers with pre-existing insulin sensitivity concerns should monitor fasting glucose. Standard research protocols range from 10–25mg daily, with many researchers running MK-677 continuously for 3–12 months.